Programs
Celvistro
NeurologyGene therapy for spinal muscular atrophy type 2
Manufacturer: Meridian PharmaceuticalsHub: CarePoint Hub ServicesLaunched: Jan 10, 2026
88
Healthy
Active Cases
16
Completed
1
Stalled
3
19% stall rate
Handoff Stalls
1
Across all transitions
Status Pipeline
5
Referral
31%
4
Benefits
25%
4
Prior Auth
25%
0
Enrollment
0%
3
Fulfillment
19%
0
Outcome
0%
Cases
Case Ref | Status | Time in Status | SLA | Responsible | Updated |
|---|---|---|---|---|---|
| REF-2025-0684 | ReferralReferral Received | 12h | SLA Exceeded | Specialty Pharmacy | Feb 4 |
| REF-2025-0688 | ReferralReferral Validated | 4h | On Track | Specialty Pharmacy | Jan 30 |
| REF-2026-0689 | ReferralReferral Received | 12h | SLA Exceeded | Specialty Pharmacy | Jan 29 |
| REF-2025-0693 | BenefitsBI Complete | 2d | Approaching SLA | Payer | Jan 28 |
| REF-2026-0692 | Prior AuthPA Denied — Appeal | 3d | On Track | Payer | Jan 20 |
| REF-2025-0691 | ReferralReferral Validated | 8h | Approaching SLA | Specialty Pharmacy | Jan 10 |
| REF-2025-0694 | BenefitsBI Initiated | 19h | On Track | Specialty Pharmacy | Jan 1 |
| REF-2025-0696 | FulfillmentShipped | 4d | SLA Exceeded | Specialty Pharmacy | Jan 1 |
| REF-2025-0683 | FulfillmentDelivered | 22h | Approaching SLA | Specialty Pharmacy | Dec 31 |
| REF-2025-0686 | ReferralReferral Validated | 4h | On Track | Specialty Pharmacy | Dec 27 |
| REF-2025-0685 | Prior AuthPA Denied — Appeal | 6h | On Track | Payer | Dec 15 |
| REF-2025-0697 | Prior AuthPA Denied — Appeal | 5d | Approaching SLA | Payer | Dec 8 |
| REF-2025-0682 | BenefitsBI Initiated | 1d | Approaching SLA | Specialty Pharmacy | Dec 6 |
| REF-2025-0690 | BenefitsBI Complete | 14h | On Track | Payer | Dec 4 |
| REF-2025-0695 | FulfillmentDelivered | 11h | On Track | Specialty Pharmacy | Dec 4 |
| REF-2025-0687 | Prior AuthPA Denied — Final | 1d | Approaching SLA | Payer | Nov 28 |
Stall Breakdown
BI Complete → PA Submitted
1 case stalled
Expected: 1dActual: 2d
Specialty Pharmacy: 1